Option Care Health (OPCH) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving Option Care Health (OPCH) right now is Acute infusion demand and hospital partnerships: Acute revenue, covering therapies like anti-infectives and nutrition support delivered after hospital discharge, has been growing at high single digits. Revenue (TTM) is ~$5.7B. If that keeps playing out, the setup is favourable; the risk to it is the most immediate risk is the drug-portfolio (CID) headwind, an estimated 600 basis point revenue drag and roughly $55 million gross-profit hit in 2026 tied to Stelara and biosimilar transitions and heavier patient benefit reverification workloads. No one can predict where OPCH trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Option Care Health (OPCH) higher?
1. Acute infusion demand and hospital partnerships
Acute revenue, covering therapies like anti-infectives and nutrition support delivered after hospital discharge, has been growing at high single digits. As health systems push to move care out of expensive hospital settings, Option Care's national footprint positions it to capture referral volume and consolidate patients, including some exiting CVS Coram's acute business.
2. Margin and cost discipline holding profit targets
Despite a low-single-digit revenue backdrop, management maintained full-year adjusted EBITDA guidance of roughly $480 to $505 million and adjusted EPS of about $1.82 to $1.92, implying mid-single-digit EBITDA and high-single-digit EPS growth at the midpoint. The mix shift toward higher-margin acute work and operating leverage support this even as chronic revenue softens.
3. Cash generation and capital allocation
The company converts earnings into meaningful free cash flow, with trailing levered free cash flow near $170 million and analyst estimates in the $300 million range looking forward. That cash has funded buybacks and tuck-in acquisitions like Intramed Plus, giving management levers to compound per-share value while the top line is muted.
4. Structural tailwind from site-of-care migration
The broader home-infusion market is estimated to grow at a mid-single-digit to low-double-digit rate as payers and patients favor lower-cost home settings over hospitals and clinics. As the scaled independent leader, Option Care is a natural consolidator in a fragmented field of regional and hospital-affiliated providers.
What could weigh on OPCH?
The most immediate risk is the drug-portfolio (CID) headwind, an estimated 600 basis point revenue drag and roughly $55 million gross-profit hit in 2026 tied to Stelara and biosimilar transitions and heavier patient benefit reverification workloads. Because infusion revenue carries large drug pass-through costs, gross margins are thin and sensitive to reimbursement changes, payer contract terms, and manufacturer distribution economics. Competition from CVS Coram, Optum-affiliated Naven Health, and hospital-owned programs pressures pricing and referral flow. Broader policy risk around drug pricing, Medicare and Medicaid rates, and specialty-pharmacy reimbursement could compress economics. Management framed the census reset as a one-time 2026 event with no 2027 carryover, but if chronic declines persist, growth and the profit guidance could come under renewed pressure.
Where OPCH trades today
A forecast starts from where the stock actually is. These are OPCH's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for OPCH as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a OPCH forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the OPCH guide and whether OPCH is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the OPCH outlook
The bottom line: what is driving Option Care Health (OPCH) is Acute infusion demand and hospital partnerships, with revenue (ttm) at ~$5.7B. If that keeps playing out the setup is favourable; the risk is the most immediate risk is the drug-portfolio (CID) headwind, an estimated 600 basis point revenue drag and roughly $55 million gross-profit hit in 2026 tied to Stelara and biosimilar transitions and heavier patient benefit reverification workloads. No one can predict the price, so treat any OPCH forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around OPCH with Walnut
Use Option Care Health as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Option Care Health (OPCH)?
+
No one can reliably predict where OPCH will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Option Care Health higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive OPCH higher?
+
The main growth drivers are Acute infusion demand and hospital partnerships; Margin and cost discipline holding profit targets; Cash generation and capital allocation. Whether they play out is the real question, not a guaranteed path.
What are the risks to OPCH?
+
The most immediate risk is the drug-portfolio (CID) headwind, an estimated 600 basis point revenue drag and roughly $55 million gross-profit hit in 2026 tied to Stelara and biosimilar transitions and heavier patient benefit reverification workloads. Because infusion revenue carries large drug pass-through costs, gross margins are thin and sensitive to reimbursement changes, payer contract terms, and manufacturer distribution economics. Competition from CVS Coram, Optum-affiliated Naven Health, and hospital-owned programs pressures pricing and referral flow. Broader policy risk around drug pricing, Medicare and Medicaid rates, and specialty-pharmacy reimbursement could compress economics. Management framed the census reset as a one-time 2026 event with no 2027 carryover, but if chronic declines persist, growth and the profit guidance could come under renewed pressure.
Will OPCH stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Option Care Health's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is OPCH a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the OPCH "is it a buy?" page for a framework. Walnut is not an investment adviser.
Why is OPCH revenue barely growing in 2026?
+
Management cited a roughly 600 basis point headwind from its acute chronic-inflammatory-drug (CID) portfolio, including Stelara and biosimilar census resets and heavier benefit reverification work. Acute therapy is growing high single digits while chronic revenue has declined slightly.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.